LXEO: Lexeo Therapeutics, Inc. Stock

by  •  • Comments Off on LXEO: Lexeo Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 88.78
Enterprise Value ($M) 59.87
Book Value ($M) 88.11
Book Value / Share 2.66
Price / Book 1.01
NCAV ($M) 67.70
NCAV / Share 2.04
Price / NCAV 1.31

Profitability (mra)
Return on Invested Capital (ROIC) -1.12
Return on Assets (ROA) -0.51
Return on Equity (ROE) -0.60

Liquidity (mrq)
Quick Ratio 3.42
Current Ratio 3.42

Balance Sheet (mrq) ($M)
Current Assets 105.27
Assets 125.69
Liabilities 37.58
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -105.77
Net Income -98.33

Cash Flow Statement (mra) ($M)
Cash From Operations -81.15
Cash from Investing -94.08
Cash from Financing 88.78

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
1 day ago 13G/A Janus Henderson Group Plc 13.70 5.04
2 days ago 13G/A Mizuho Financial Group Inc 6.60 14.40
3 days ago 13G/A Adage Capital Management, L.P. 0.70 -89.23
04-28 13G Integrated Core Strategies (us) Llc 5.80
02-14 13G/A Omega Fund VI, L.P. 3.60 -45.10
02-14 13G/A Eventide Asset Management, Llc 3.73 -33.47
02-04 13G BlackRock, Inc. 5.50
11-14 13G/A Lundbeckfond Invest A/S 2.90 -48.66
11-14 13G/A Longitude Capital Partners IV, LLC 8.40 7.72

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-12 10-Q PART I-FINANCIAL INFORMATION PART II-OTHER INFORMATION SIGNATURES
2025-03-24 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURS

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-14 249,419 924,268 26.99
2025-05-13 229,813 792,748 28.99
2025-05-12 142,012 948,146 14.98
2025-05-09 202,369 912,686 22.17

(click for more detail)

Similar Companies
LGND – Ligand Pharmaceuticals Incorporated LNTH – Lantheus Holdings, Inc.
LRMR – Larimar Therapeutics, Inc. MDWD – MediWound Ltd.
MIRM – Mirum Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io